Clinical Nuclear Medicine · 2010 · 16 citations · 7 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic RadiologyHybrid ImagingBreast ImagingPositron Emission TomographyProstate BiopsyProstate CancerProstate Cancer ImagingTumor DetectionInformed ConsentMammary Tumor ImagingOncologic Pet ImagingPet AcquisitionProstate Biopsy DiagnosisProstate Cancer DiagnosisProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen Positron Emission Tomography
There is growing experience with F-18 fluorocholine (FCH) for positron emission tomography/computed tomography (PET/CT) imaging of prostate cancer, but limited experience in breast cancer. We report the PET detection of synchronous cancers of the breast and prostate. A 68-year-old man with elevated prostate specific antigen levels underwent PET/CT following injection of 4.7 mCi of FCH with informed consent as part of a clinical research study. PET/CT revealed focal uptake in the left breast that was found by biopsy to be an invasive ductal breast carcinoma. Prostate biopsy also revealed prostate cancer corresponding to an area of increased prostatic FCH uptake. The patient received primary treatments with mastectomy and prostatectomy.
7
Ana Ramı́rez de Molina, Agustı́n Rodrı́guez-González, Ruth Gutiérrez et al. · Biochemical and Biophysical Research Communications · 2002 · 339 citations
Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
Timothy R. DeGrado, S. W. BALDWIN, S Wang et al. · PubMed · 2001 · 334 citations
Medicine, Oncology, Pharmacology +14
Pharmacokinetics and radiation dosimetry of 18F-fluorocholine.
Timothy R. DeGrado, Robert E. Reiman, David T. Price et al. · PubMed · 2002 · 181 citations
Medicine, Nuclear Medicine, Oncology +15